ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,781 to 4,800 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Treatment vs Placebo: Rate of Death1 of 645

1 of 641

-0.0 points

-0.7 to 0.7

1,286NCT04308668

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Treatment vs Placebo: Rate of Hospitalization5 of 645

9 of 641

-0.6 points

-1.9 to 0.6

1,286NCT04308668

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint22 of 641

19 of 643

0.5 points

-1.5 to 2.5

1,284NCT04508023

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Rivaroxaban 10 Milligrams (mg) vs Placebo: Number of Participants Who Were Hospitalized or Dead on Day 355 of 641

3 of 643

0.3 points

-0.7 to 1.4

1,284NCT04508023

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Rivaroxaban 10 Milligrams (mg) vs Placebo: deaths from any cause2 of 641

2 of 643

0.0 points

-0.8 to 0.8

1,284NCT04508023

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

Intervention Arm (HITSystem 2.1) vs Control Arm (Standard of Care): Viral Suppression655 of 703

535 of 581

1.1 points

-1.8 to 4.1

1,284NCT04571684

Evaluating HITSystem 2.1 to Improve Viral Suppression in Kenya

LHRHa + TAK-700 vs LHRHa + Bicalutamide: deaths from any cause251 of 638

274 of 641

-3.4 points

-8.8 to 2.0

1,279NCT01809691

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)169 of 849

118 of 430

-7.5 points

-12.6 to -2.6

1,279NCT02269475

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

MEDI3250 vs Placebo: the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)0 of 849

1 of 430

-0.2 points

-1.3 to 0.3

1,279NCT02269475

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

Placebo + Letrozole 2.5 mg vs Lapatinib 1500 mg + Letrozole 2.5 mg: deaths from any cause23 of 624

18 of 654

0.9 points

-1.0 to 3.0

1,278NCT00073528

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Placebo + Letrozole 2.5 mg vs Lapatinib 1500 mg + Letrozole 2.5 mg: serious adverse events103 of 624

150 of 654

-6.4 points

-10.8 to -2.1

1,278NCT00073528

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Clinical Cure at TOC in the CE-TOC Populations611 of 641

617 of 637

-1.5 points

-3.8 to 0.6

1,278NCT03788967

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Old Lina vs New Lina: Number of Patients With HbA1c<6.5% Over Time139 of 904

74 of 373

-4.5 points

-9.3 to 0.0

1,277NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With HbA1c<7.0% Over Time382 of 904

172 of 373

-3.9 points

-9.8 to 2.1

1,277NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Old Lina vs New Lina: Number of Patients With Lowered HbA1c by at Least 0.5% Over Time155 of 904

175 of 373

-29.8 points

-35.3 to -24.1

1,277NCT00736099

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Arm C - Fluticasone vs Arm C - Placebo: Number of Participants With Hospitalization or Death3 of 656

3 of 621

-0.0 points

-1.0 to 0.9

1,277NCT05736874

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Arm C - Fluticasone vs Arm C - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death24 of 656

13 of 621

1.6 points

-0.3 to 3.5

1,277NCT05736874

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Arm C - Fluticasone vs Arm C - Placebo: serious adverse events3 of 656

7 of 621

-0.7 points

-1.9 to 0.4

1,277NCT05736874

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Cervarix Group Without HPV-18 6-Month Persistent Infection vs Cervarix Group With HPV-18 6-Month Persistent Infection: Number of Seroconverted Subjects for Anti-HPV-18 Without and With 6-month Persistent Infection.1,242 of 1,248

28 of 28

-0.5 points

-1.0 to 11.6

1,276NCT00122681

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Who Reporting Monitoring BP at Least 2 Times Per Week at Six Months Follow-up189 of 673

265 of 603

-15.9 points

-21.0 to -10.6

1,276NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=240"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=240

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04308668-55245cee",
        "title": "Treatment vs Placebo: Rate of Death",
        "summary": "1 of 645 against 1 of 641; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT04308668, Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2",
        "record": "/library/comparisons/NCT04308668-55245cee",
        "nct_id": "NCT04308668",
        "kind": "outcome",
        "participants": 1286,
        "risk_difference": {
          "value": -0.000009674805596875113,
          "lower": -0.007344873750816434,
          "upper": 0.007283143480424106
        },
        "group_1": "1 of 645",
        "group_2": "1 of 641",
        "difference": "-0.0 points",
        "interval": "-0.7 to 0.7",
        "trial_title": "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2"
      },
      {
        "id": "NCT04308668-fe9f6202",
        "title": "Treatment vs Placebo: Rate of Hospitalization",
        "summary": "5 of 645 against 9 of 641; risk difference -0.6 points, 95% interval -1.9 to 0.6; NCT04308668, Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2",
        "record": "/library/comparisons/NCT04308668-fe9f6202",
        "nct_id": "NCT04308668",
        "kind": "outcome",
        "participants": 1286,
        "risk_difference": {
          "value": -0.006288623637968775,
          "lower": -0.01948323432093614,
          "upper": 0.00593490790352481
        },
        "group_1": "5 of 645",
        "group_2": "9 of 641",
        "difference": "-0.6 points",
        "interval": "-1.9 to 0.6",
        "trial_title": "Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=241",
  "request_id": "rQtdokMDmwJ-ggJY"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?